HistoneH3(mutatedK27Met)抗体;HistoneH3(mutatedK27Met) Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Histone H3 (mutated K27 Met) expression in recombinant protein lysate.    

  
  

The Histone H3K27M mutation, where lysine 27 is replaced by methionine (K27M), is a hallmark of certain aggressive cancers, particularly diffuse midline gliomas (DMGs) and diffuse intrinsic pontine gliomas (DIPGs) in children. This oncohistone mutation disrupts epigenetic regulation by inhibiting the polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), a mark associated with transcriptional silencing. The H3K27M mutation causes global reduction of H3K27me3. leading to aberrant gene expression and tumorigenesis.

Antibodies specific for Histone H3K27M are critical tools for detecting this mutation in research and diagnostics. They enable precise identification of H3K27M-altered tumors through techniques like immunohistochemistry (IHC) or Western blot, aiding in tumor classification and prognostication. These antibodies are designed to recognize the unique epitope created by the K27M substitution, ensuring specificity over wild-type H3. Their development has been pivotal in advancing understanding of H3K27M-driven oncogenesis and evaluating therapeutic strategies targeting epigenetic dysregulation. Clinically, H3K27M detection serves as a diagnostic biomarker, as the mutation is now integrated into the WHO classification of central nervous system tumors. Researchers also use these antibodies to study the mutation's role in altering chromatin structure, cellular differentiation, and tumor progression in preclinical models.